Microeconomics › Section M · Positive externalities and public goods › Topic M.1

Investment in innovation as a positive externality

A new idea is a strange product: the inventor pays all the cost of creating it, then watches the benefit leak to everyone who copies, learns and builds on it. That leak is why markets systematically underinvest in innovation - and why societies that want new technology must design ways to pay for it.

The spillover problem

Innovation is the textbook positive externality at its largest. Research produces knowledge, and knowledge is a leaky vessel: once an idea exists, others copy it, learn from it, build on it and improve it - none of whom paid for its creation. The inventor's ledger records the full cost and only a slice of the benefit; society's ledger records nearly all the benefit. Left to itself, the market invests up to the point where the PRIVATE return covers the cost - falling short of where the SOCIAL return would justify it. Every tool this section examines answers one question: how does a society pay for the leak?

What private incentive remains

The market does not produce zero innovation, and it is worth seeing why not. An innovative firm enjoys a temporary edge: producing more cheaply, or offering characteristics rivals cannot yet match, it earns above-normal profits until the competition catches up. Speed and secrecy help - the first mover captures the market's attention, and the recipe stays hidden for a while. Patents help by making the temporary edge legal, as the monopoly section saw. These props sustain real private investment - much of the consumer-technology industry rests on them - but they only partially plug the leak, and the next card shows what leaks through.

The copying problem

Consider a pharmaceutical firm weighing a new drug: studies from 2016-2020 put the cost of bringing one to market, counting failures, at about $1 billion to over $2 billion, after more than a decade of research and testing. If it fails, the firm bears the whole loss. If it succeeds, competitors study the molecule, adapt the idea, and copy it once protection lapses. Economic studies find that original inventors capture only about a third to a half of their innovations' total benefits; the rest goes to other firms and users. Private incentive, alone, funds invention only up to the leak.

The financial-capital framing

Economists draw the underinvestment with the market for money itself. A firm's demand for R&D funds reflects the projects it expects to PROFIT from privately - the private demand curve for financial capital, sloping down against the interest rate. Add the spillovers - ideas sparking other ideas, suppliers, customers, future innovators - and the SOCIAL demand curve sits above it everywhere. At any interest rate, the social optimum borrows more than the private market will: the vertical gap between the curves is the uncompensated benefit of the marginal research dollar, and the horizontal distance is innovation that never gets funded.

Worked example: reading the two curves

A firm's R&D division can invest at these scales (millions) at interest rates: private demand: 3% -> $60m, 6% -> $42m, 9% -> $25m, 12% -> $10m. Social demand - adding spillovers - runs 3% -> $90m, 6% -> $66m, 9% -> $45m, 12% -> $22m. 1. At 9%, the firm borrows $25m - where private return meets the interest rate. 2. Society would want $45m at the same rate - the projects between 25 and 45 are worth funding: their social return clears 9%, their private return does not. 3. The gap at each rate: $30m, $24m, $20m, $12m - large at low rates, shrinking as money gets dear. 4. The fix's mechanism: make the firm's private curve look more like the social one - a subsidy, or rights that capture more of the benefit, both in the next topic. Assumptions: the table's rates as the relevant range.

Spillovers in consumption: the flu shot

The same gap appears on the consumption side. A flu shot's private benefit is protection for the person vaccinated; the social benefit adds everyone they would otherwise have infected - and everyone those would have infected. Marginal social benefit exceeds marginal private benefit by the spillover, so the market quantity sits below the social optimum: underproduced and underconsumed, as the externality analysis predicts. The vaccine case also shows why positive externalities can be urgent: the gap widens when transmission is fast, which is why public health treats vaccination as policy, not just a product.

Worked example: pricing a spillover fix

A flu shot costs $40 to supply at any quantity. Willingness to pay runs \(MPB = 60 - 0.05Q\) (thousands of shots). 1. Market equilibrium: \(60 - 0.05Q = 40\), so \(Q = 400\) thousand, price $40. 2. The social benefit adds $15 per shot: \(MSB = 75 - 0.05Q\). 3. Social optimum: \(75 - 0.05Q = 40\), so \(Q = 700\) - the market leaves 300 thousand worth vaccinating. 4. The fix: a voucher worth $15. Consumers pay only $25 out of pocket, and demand at $25 gives \(Q = 700\) - exactly the social optimum. 5. Check: the voucher is a Pigouvian subsidy, sized to the spillover. Suppliers receive $40 a shot; the government pays \(15 \times 700\) thousand = $10.5 million, which lifts vaccination by 300 thousand. Assumptions: spillover constant at $15; supply flat at $40.

Human capital: education as investment

Education is investment in human capital - the skills inside people - and it shows the same two-ledger pattern. The private case is strong on its own: economists estimate the return to a college education at roughly 10 to 15 percent a year, and more educated workers earn substantially more across virtually every dataset. But the private return is not the whole return: education spills over to the society that receives a more productive workforce, better-informed citizens, colleagues who train each other, and - on many measures - lower crime and better health. The social return exceeds the private one, which is why every rich country subsidises schooling.

The public sector as founder

A look inside the smartphone in a pocket makes the point concrete: its smartest components - the internet's foundations, satellite positioning, touchscreens, voice recognition - trace back to publicly funded research, often military in origin, decades before any consumer product. Economists such as Mariana Mazzucato have argued that the state is not merely a fixer of market failures in innovation but often the daring early investor that bears the risks private capital will not. The claim is debated in its stronger versions, but the historical core is not: much foundational technology began as public research, funded by an investor that does not need private returns.

Common mistakes to avoid

First, treating patents as the opposite of the externality: they are its partial fix, trading a temporary monopoly for disclosure. Second, confusing 'the market underinvests' with 'the market invests nothing': private incentives are real, just too small. Third, measuring research only by the private return - the leak IS the social value, not a loss from society's ledger. Fourth, forgetting that spillovers occur in consumption too: vaccination is the model case. Fifth, expecting one tool to fix everything: patents, subsidies, public research and education funding each repair a different slice of the same leak.

Key takeaways

Innovation is the positive externality at scale: the innovator pays the full cost and captures only a slice of the benefit - the rest leaks to imitators, learners and builders, so markets underinvest. What private incentive remains is real but partial: a temporary edge earning above-normal profits, propped by patents. The financial-capital picture shows the gap directly: at 9% funds, the worked firm borrows $25 million where society wants $45 million - $20 million of worthwhile research unfunded. Consumption-side spillovers run the same arithmetic: the flu shot's $15 external benefit means the market's 400 thousand shots should be 700 thousand, and a voucher equal to the spillover reaches the optimum. Education shows the pattern in human capital, and the smartphone's public-research foundations show the state as the frontier's early investor.

Flashcards

Flashcard

Knowledge as a leaky vessel

Once an idea exists, others copy and build without paying

The positive externality at its largest.

Test your understanding

Question 1 of 5

Why do markets underinvest in innovation relative to the social optimum?

Question 2 of 5

In the worked example, at a 9% cost of funds the firm borrows $25 million while society would want $45 million. What is the gap, and what does it represent?

Question 3 of 5

A flu shot costs $40 to supply; private willingness to pay is 60 - 0.05Q and the spillover is $15 per shot. What voucher size reaches the social optimum of 700 thousand shots?

Question 4 of 5

Why does education merit public subsidy on externality grounds, given its strong private return?

Question 5 of 5

What is the core of Mazzucato's argument about the state's role in innovation?

← Previous topicNext topic →